Thomas E. Scammell

Thomas E. Scammell

Auto-generated profile, based on publicly available information

Thomas E. Scammell

Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Neuron
Verified
Journal Article
Closed access
TSThomas E. Scammell
Thomas E. Scammell
EAElda Arrigoni
Elda Arrigoni
JLJonathan O. Lipton
Jonathan O. Lipton

22 December 2005 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
KYKyoko Yoshida
Kyoko Yoshida
SMSarah McCormack
Sarah McCormack
RERodrigo A. España
Rodrigo A. España
ACAmanda Crocker
Amanda Crocker
TSThomas E. Scammell
Thomas E. Scammell

31 December 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
TSThomas E. Scammell
Thomas E. Scammell
Narcolepsy affects approximately 1 in 2000 people but is often not correctly diagnosed. This review article summarizes recent discoveries regarding the neurobiologic features of this condition and describes a practical clinical approach to effective treatment.

10 February 2011 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
TSThomas E. Scammell
Thomas E. Scammell
CWChristopher J. Winrow
Christopher J. Winrow
Orexin-A and -B (also known as hypocretin-1 and -2) are neuropeptides produced in the lateral hypothalamus that promote many aspects of arousal through the OX1 and OX2 receptors. In fact, they are necessary for normal wakefulness, as loss of the orexin-producing neurons causes narcolepsy in humans and rodents. This has generated considerable interest in developing small-molecule orexin receptor antagonists as a novel therapy for the treatment of insomnia. Orexin antagonists, especially those that block OX2 or both OX1 and OX2 receptors, clearly promote sleep in animals, and clinical results are encouraging: Several compounds are in Phase III trials. As the orexin system mainly promotes arousal, these new compounds will likely improve insomnia without incurring many of the side effects encountered with current medications.

13 December 2018 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
CMCarrie E. Mahoney
Carrie E. Mahoney
ACAndrew Cogswell
Andrew Cogswell
IKIgor J. Koralnik
Igor J. Koralnik
TSThomas E. Scammell
Thomas E. Scammell

25 October 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
ACA. Crocker
A. Crocker
RER. A. España
R. A. España
MPM. Papadopoulou
M. Papadopoulou
CSC. B. Saper
C. B. Saper
JFJ. Faraco
J. Faraco
TST. E. Scammell
T. E. Scammell
Background: Narcolepsy with cataplexy is associated with a loss of orexin/hypocretin. It is speculated that an autoimmune process kills the orexin-producing neurons, but these cells may survive yet fail to produce orexin. Objective: To examine whether other markers of the orexin neurons are lost in narcolepsy with cataplexy. Methods: We used immunohistochemistry and in situ hybridization to examine the expression of orexin, neuronal activity-regulated pentraxin (NARP), and prodynorphin in hypothalami from five control and two narcoleptic individuals. Results: In the control hypothalami, at least 80% of the orexin-producing neurons also contained prodynorphin mRNA and NARP. In the patients with narcolepsy, the number of cells producing these markers was reduced to about 5 to 10% of normal. Conclusions: Narcolepsy with cataplexy is likely caused by a loss of the orexin-producing neurons. In addition, loss of dynorphin and neuronal activity-regulated pentraxin may contribute to the symptoms of narcolepsy.